問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

Division of Thoracic Medicine

List

193Cases

2010-05-01 - 2012-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-10-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2010-06-01 - 2012-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-10-01 - 2014-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2011-08-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-06-30 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2016-01-01 - 2017-04-25

Others

A 24-week Treatment, Randomised, Parallel-group, Double blinded, DoubleDummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium bromide/Formoterol fumarate compared with Individual Components and Placebo and Aclidinium bromide compared with Placebo when Administered to Patients with Stable Chronic Obstructive Pulmonary Disease

  • Condition/Disease

    Stable Chronic Obstructive Pulmonary Disease

  • Test Drug

    Aclidinium bromide/Formoterol fumarate

Participate Sites
8Sites

Recruiting1Sites

Terminated5Sites

Study ended1Sites

2015-06-02 - 2019-11-30

Phase II

A Phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lung cancer (NSCLC) and BDX004 Positive Label.

  • Condition/Disease

    NSCLC

  • Test Drug

    Ficlatuzumab (AV-299),

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2015-01-01 - 2018-12-31

Phase III

Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral nintedanib plus docetaxel therapy compared to placebo plus docetaxel therapy in patients with stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer after failure of first line chemotherapy

  • Condition/Disease

    stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer

  • Test Drug

    Nintedanib

Participate Sites
6Sites

Terminated6Sites

2020-08-07 - 2022-07-01

Phase II

A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection

  • Condition/Disease

    Severe Influenza Infection

  • Test Drug

    DAS181

Participate Sites
4Sites

Recruiting4Sites

1 13 14 15 16 17 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB